NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free XBI Stock Alerts $84.65 -0.96 (-1.12%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$84.55▼$86.3050-Day Range$84.65▼$102.9352-Week Range$63.80▼$103.52Volume11.84 million shsAverage Volume11.72 million shsMarket Capitalization$6.58 billionAssets Under Management$6.41 billionDividend Yield0.02%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get SPDR S&P Biotech ETF alerts: Email Address About SPDR S&P Biotech ETF (NYSEARCA:XBI)SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XBI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBI ETF News HeadlinesApril 16, 2024 | americanbankingnews.comInvestors Buy High Volume of SPDR S&P Biotech ETF Put Options (NYSEARCA:XBI)March 28, 2024 | msn.com2 Top Biotech Buyout CandidatesApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024March 19, 2024 | investorplace.com3 Biotech ETFs Overdue for a BounceFebruary 29, 2024 | msn.comBiotech Stocks Are on a Tear. They Could Keep Climbing.February 28, 2024 | wsj.comHeard on the Street Recap: Zooming UpFebruary 13, 2024 | reuters.comSpdr S&P Biotech EtfApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.February 10, 2024 | investing.comXBI ETF Stock Price HistorySee More Headlines Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings139 Fund Statistics Assets Under Management$6.41 billion Average Daily Volume$11.20 million Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume96,050 Put Options59,124 Call Options36,926 Short Interest53,110,000 shs Miscellaneous Outstanding Shares77,680,000Beta1.08 Creation Unit50,000 Creation Fee$250.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.35%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.35%0.60%0.60%0.58%0.58% SPDR S&P Biotech ETF (XBI) Holdings & ExposureTop 10 XBI HoldingsAlpine Immune Sciences(NASDAQ:ALPN)Holding Weight: 1.80%Exact Sciences(NASDAQ:EXAS)Holding Weight: 1.30%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.22%Cytokinetics(NASDAQ:CYTK)Holding Weight: 1.19%BioMarin Pharmaceutical(NASDAQ:BMRN)Holding Weight: 1.17%Natera(NASDAQ:NTRA)Holding Weight: 1.16%Crinetics Pharmaceuticals(NASDAQ:CRNX)Holding Weight: 1.15%Exelixis(NASDAQ:EXEL)Holding Weight: 1.12%Roivant Sciences(NASDAQ:ROIV)Holding Weight: 1.12%Cerevel Therapeutics(NASDAQ:CERE)Holding Weight: 1.11%XBI Sector ExposureXBI Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsiShares Biotechnology ETFNASDAQ:IBBiShares U.S. Medical Devices ETFNYSEARCA:IHIiShares Global Healthcare ETFNYSEARCA:IXJiShares U.S. Healthcare ETFNYSEARCA:IYHFidelity MSCI Health Care Index ETFNYSEARCA:FHLCInstitutional OwnershipFiduciary Alliance LLCBought 1,789 shares on 4/17/2024Ownership: 0.030%Founders Financial Securities LLCBought 337 shares on 4/17/2024Ownership: 0.007%Hennion & Walsh Asset Management Inc.Bought 2,035 shares on 4/17/2024Ownership: 0.006%Firethorn Wealth Partners LLCSold 369 shares on 4/16/2024Ownership: 0.009%Financial Management Professionals Inc.Bought 271 shares on 4/16/2024Ownership: 0.001%View All Institutional Transactions XBI ETF - Frequently Asked Questions How have XBI shares performed in 2024? SPDR S&P Biotech ETF's stock was trading at $89.29 on January 1st, 2024. Since then, XBI shares have decreased by 5.2% and is now trading at $84.65. View the best growth stocks for 2024 here. What does XBI invest in? SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $6.41 billion assets under management. What stocks does SPDR S&P Biotech ETF hold? XBI invests in 139 holdings. Some of the stocks in their portfolio include Alpine Immune Sciences (ALPN), Exact Sciences (EXAS), Revolution Medicines (RVMD), Cytokinetics (CYTK), BioMarin Pharmaceutical (BMRN), Natera (NTRA), Crinetics Pharmaceuticals (CRNX), Exelixis (EXEL), Roivant Sciences (ROIV) and Cerevel Therapeutics (CERE). What is the management fee for SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX). Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Alaska Permanent Fund Corp (1.13%), Wealth Enhancement Advisory Services LLC (0.15%), Edge Wealth Management LLC (0.14%), Parkside Investments LLC (0.12%), CMH Wealth Management LLC (0.09%) and Marotta Asset Management (0.08%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:XBI) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaTop 5 AI Stocks to Buy for 2024Market Moving TrendsBiden out June 13; Kamala won’t replace him?Paradigm PressUrgent alert: open this for a huge profit potentialTimothy SykesOptions trading has suddenly become more reliable.Eagle PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsForget Nvidia, buy this A.I. Stock NowInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.